LORF9 of Marek's disease virus is involved in the early cytolytic replication of B lymphocyte and can act as a target for gene deletion vaccine development.

deletion mutant has a comparative immunological protective effect with CVI988/Rispens vaccine strain against very virulent MDV challenge. This is a significant discovery that LORF9 can be exploited as a possible target for the development of an MDV gene deletion vaccine.